Cipla appeals against Onbrez decision

Cipla has appealed against a decision by the Delhi High Court that blocked the generic drug maker from marketing copies of Novartis’s respiratory drug Onbrez (indacaterol) in India.

A spokesperson for Novartis told LSIPR that India-based Cipla filed an appeal on January 13 requesting that the interim injunction imposed against it be vacated.

Last week, the Indian court barred Cipla from selling a generic version of Novartis’s Onbrez drug.

Novartis sued Cipla for patent and trademark infringement last autumn, shortly after Cipla launched its version of the drug—dubbed ‘Unibrez’.

The Novartis spokesperson added that the company welcomes the litigation’s outcome and that the main court action dealing with the alleged infringement of the patent will continue.